[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584439":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":26,"centralContacts":26,"locations":34,"responsibleParty":46,"collaborators":26,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":26,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":26,"enrollmentInfo":58,"targetDuration":26,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":26,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Handok Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HD-P023","EXPERIMENTAL","One tablet of HD-P023 by oral",[13],"Drug: HD-P023",{"label":15,"type":16,"description":17,"interventionNames":18},"Co-administration of Teneligliptin and Empagliflozin High","ACTIVE_COMPARATOR","One tablet each of Teneligliptin and Empagliflozin High by oral",[19,20],"Drug: Teneligliptin","Drug: Empagliflozin High",[22,27,31],{"type":23,"name":9,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Single dose administration of HD-P023",[9],null,{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Teneligliptin","Single does administration of Teneligliptin and Empagliflozin High",[15],{"type":23,"name":32,"description":29,"armGroupLabels":33,"otherNames":26},"Empagliflozin High",[15],[35],{"facility":36,"status":26,"city":37,"state":37,"zip":38,"country":39,"countryCode":26,"cosmosGeoPoint":40,"geoPoint":45,"contacts":26},"H Plus Yangji Hospital","Seoul","08779","South Korea",{"type":41,"coordinates":42},"Point",[43,44],126.9784,37.566,{"lat":44,"lon":43},{"type":47,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100584439","phase-1-pharmacokinetics-and-safety-of-hd-p023-and-co-administration-of-teneligliptin-and-empagliflozin-high-in-healthy-volunteers-100584439",false,"NCT06889350","Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers","A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of HD-P023 in Comparison With Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers","Inclusion Criteria:\n\n* Patients who are 19 years or older on screening\n* Signed informed consent\n* Healthy Volunteer\n* Other inclusion applies\n\nExclusion Criteria:\n\n* Clinically relevant\u002Fsignificant findings as evaluated by the investigator\n* Other exclusion applied",true,"ALL","19 Years",{"count":59,"type":60},40,"ACTUAL","INTERVENTIONAL",[63],"PHASE1","The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers",[66],"Healthy Volunteers","COMPLETED","2025-07-30",{"date":70,"type":60},"2025-07-31",{"date":72,"type":60},"2025-03-26",{"date":74,"type":60},"2025-05-07",{"name":5,"class":6},1]